The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Molecular profiling in squamous anal carcinoma
Squamous anal carcinoma is considered to be a rare disease and currently has few treatment options, where few patients response to checkpoint inhibitors. Cristina Smolenski, MD, Gustave Roussy, Villejuif, France, comments on findings from a molecular profiling study of patients with squamous anal carcinoma. PIK3CA mutations were found in approximately a third of patients, and HR3 and high tumor mutation burden (TMB) were additionally found in patients. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
